Skip to content

At Home Wearable Sensors and Smartphone for Stroke Survivors With Upper Limb Motor Challenges.

Motivation-Induced Movement Therapy: Enhancing Upper Limb Engagement in Stroke Survivors Through Ring Sensors and Data Visualization.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06787729
Enrollment
50
Registered
2025-01-22
Start date
2026-04-20
Completion date
2027-07-31
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

Hemiparesis, Upper extremity, Weakness, Arm, Hand, Ring Sensor, Wrist Sensor, mHealth, Stroke, Activities of daily living

Brief summary

The goal of this clinical trial is to learn if wearable sensor data visualization on smartphones can improve the use of the stroke-affected limb during everyday activities. Chronic stroke survivors (\>12 months from onset) ages 18-80 years old with residual upper extremity motor impairments may be eligible to participate. The main question it aims to answer is: Does the mobile health (mHealth) intervention help to improve the use of the stroke-affected upper-limb during daily living? The study is designed so each participant serves as their own control. Researchers will compare information from the baseline and intervention time periods to see if visualizing the data on the smartphone impacts the participant's daily use of the arm. Participants will be asked to wear a set of wearable ring and wrist sensors and interact with a custom-designed smartphone app, aiming to increase the use of their stroke-affected limb during daily activities as much as possible. They will receive feedback from the app, communicate with study therapists, participate in goal setting, complete clinical assessments, and share about their experience using the system during a virtual interview.

Detailed description

To test the efficacy of the mHealth intervention elements (i.e., feedback, goal setting, and communication), we will use the A (Baseline)-B (Intervention) design. The A-B design allows for an analysis of the effects of the introduction of the intervention elements, while providing all participants an opportunity to experience the novel intervention components. During the baseline phase (week 0 - week 1), study participants will wear the wrist and index finger-worn sensors, bilaterally, for a total of 7 days. The app will also allow study participants to self-annotate their activities approximately every 90 minutes. During the intervention phase (week 1 - week 4), study participants will be asked to wear the wrist and/or index finger-worn sensors, bilaterally, for the next 3 weeks, similar to the baseline phase. The primary difference is that the patient will be asked to actively interact with the Intervention app, which will provide visualization of the patient's limb activity level. The platform will send auto-reminders to subjects every day at their preferred morning time to remind them to wear the wearable sensors and interact with the app. Using the sensor data collected from the wearable devices, the app will visualize the daily and weekly summary of the participants' limb activity data and the goals set by the therapist and patient. Additionally, the app will allow participants to annotate their activities and show the annotations along with the data. During the intervention phase, the participant will engage in 2 separate Zoom calls with a research therapist to 1) review the limb activity during the week, 2) discuss barriers to using the more impaired arm and ways to overcome them, 3) adjust the goal setting for the following week, and 4) document the discussions. Clinical assessments will be completed after enrollment and following the intervention phase.

Interventions

DEVICEmHealth

The experimental design is composed of two phases: baseline and intervention. During the first week (baseline), subjects will wear sensors, but no additional features (e.g., feedback, goal-setting, and weekly Zoom calls with clinicians) will be provided. For the next three weeks (intervention), subjects will wear sensors and have access to all intervention features, including weekly Zoom calls and goal-setting with clinicians. They will be encouraged to use the more impaired arm as much as possible.

Sponsors

Spaulding Rehabilitation Hospital
Lead SponsorOTHER
University of Massachusetts, Amherst
CollaboratorOTHER
University of Maryland, College Park
CollaboratorOTHER
National Institute for Biomedical Imaging and Bioengineering (NIBIB)
CollaboratorNIH

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

We will use the A (Baseline)-B (Intervention) design. Each participant will serve as their own control.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Stroke survivor (ischemic or hemorrhagic), \>12 months post stroke, at the time of consent * Aged between 18 and 80 * Ability to extend ≥ 10° at the metacarpophalangeal joint and one of the interphalangeal joints of each finger, ≥ 10° extension or abduction of the thumb, and ≥ 20° extension of the wrist from a fully flexed starting position. * Demonstrating more affected arm nonuse, defined as a MAL-AoU score of \</= 4.5. * Actively uses at least one smartphone app. * Strong beliefs towards being in control of their recovery, indicated by a score of ≤ 10 points on the Internal Recovery Locus of Control (I-RLOC) Scale. * Participants must be able to read, write, and understand English at a level sufficient to comprehend study materials and provide informed consent.

Exclusion criteria

* Cognitive impairments that may affect the ability to understand and follow instructions (score \< 24 in the Mini Mental State Examination) * Difficulties comprehending numbers, dyslexia, severe aphasia, or other neurological conditions that prohibit the use of smartphones for safety reasons. * Undergoing other types of motor therapy during the study period. * Previous participation in constraint-induced movement therapy. * Currently participating in or has participated in the past 3 months in any experimental rehabilitation or drug studies. * Use of botulinum toxin for motor disability ≤ 3 months before treatment. * Significant changes in pharmacological or treatment plans during the study period that may affect upper-limb use. * Major medical problems that could interfere with participation. * History of a disabling stroke (i.e., need more than minimum assistance to perform ADLs). * Legally blind status. * Uncontrolled seizures. * Inability to don/doff sensors independently or with the assistance of a caregiver. * Implantable medical devices that do not comply with the ISO 14117:2012 and/or ANSI/AAMI PC69 standards for electromagnetic compatibility. Subjects will be asked to provide their medical device record card, and non-compliant devices will result in exclusion from the study.

Design outcomes

Primary

MeasureTime frameDescription
Motor Activity Log - Amount of UseWeek 0, Week 1, Week 4This outcome measure assesses upper extremity function and use through patient report. Items are scored using a 6-point ordinal scale. For the Amount Scale, 0=the weaker arm was not used at all for that activity (not used), while 5=the weaker arm was used as often as before the stroke (same as pre-stroke). The score is calculated by adding the rating scores for each item and dividing by the number of items asked.
Use DurationFrom enrollment to the end of the intervention period at 4 weeksThis measure evaluates the duration for which a patient actively uses their stroke-affected limb during daily activities, as recorded by a wearable accelerometer placed on the stroke-affected index finger. The unit is minutes, with a range from 0 to 3600. A value of 0 indicates no use of the stroke-affected limb during the 24-hour period, while 3600 indicates continuous activity of the limb throughout the day. To compute Use Duration, the continuous accelerometer data is segmented into short intervals (e.g., one second), and the duration is calculated by counting the time intervals where the acceleration magnitude exceeds a threshold (e.g., \> 1.134 g).

Secondary

MeasureTime frameDescription
Motor Activity Log - Quality of MovementWeek 0, Week 1, Week 4This outcome measure assesses upper extremity function and use through patient report. Items are scored using a 6-point ordinal scale. For the How Well Scale, 0=the weaker arm was not used at all for that activity (not used), while 5=the ability to use the weaker arm for that activity was as good as before the stroke (normal). The score is calculated by adding the rating scores for each item and dividing by the number of items asked.
Use RatioFrom enrollment to the end of the intervention period at 4 weeksThis measure compares the activity levels of the stroke-affected limb to the less-affected limb. The range is from -log(3600) to log(3600). where -log(3600) indicates exclusive use of the stroke-affected limb, log(3600) indicates exclusive use of the less-affected limb, and 0 represents equal use of both limbs. Use Ratio is computed by first determining the Use Duration for both the stroke-affected and less-affected limbs using wearable accelerometers placed on their respective index fingers. The relationship is then calculated as the logarithm of the ratio of Use Durations: log(stroke-affected use duration/less-affected use duration).

Countries

United States

Contacts

CONTACTKathy Piela, PT, DPT
kpiela@mgb.org617-952-6388
PRINCIPAL_INVESTIGATORPaolo Bonato, PhD

Director of Motion Analysis Laboratory

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026